Last reviewed · How we verify

Dexlan — Competitive Intelligence Brief

Dexlan (Dexlan) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Area: Gastroenterology.

phase 1 Sterile alpha and TIR motif-containing protein 1, Cytosolic endo-beta-N-acetylglucosaminidase, Potassium-transporting ATPase Gastroenterology Small molecule Live · refreshed every 30 min

Target snapshot

Dexlan (Dexlan) — Chang Gung Memorial Hospital.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Dexlan TARGET Dexlan Chang Gung Memorial Hospital phase 1 Sterile alpha and TIR motif-containing protein 1, Cytosolic endo-beta-N-acetylglucosaminidase, Potassium-transporting ATPase
Dexilant Dexilant Genuine Research Center, Egypt marketed Sterile alpha and TIR motif-containing protein 1, Cytosolic endo-beta-N-acetylglucosaminidase, Potassium-transporting ATPase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape

No sponsor landscape data.

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Dexlan — Competitive Intelligence Brief. https://druglandscape.com/ci/dexlan. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing